Preoperative and Postoperative Approaches to Gastroesophageal Cancer: What is All the Fuss About

J Natl Compr Canc Netw. 2022 Feb;20(2):193-202. doi: 10.6004/jnccn.2021.7118.

Abstract

Gastroesophageal cancers carry poor prognoses, and are a leading cause of cancer-related morbidity and mortality worldwide. Even in those with resectable disease, more than half of patients treated with surgery alone experience disease recurrence. Multimodality approaches using preoperative and postoperative chemotherapy and/or radiotherapy have been established, resulting in incremental improvements in outcomes. Globally, there is no standardized approach, and treatment varies with geographic location. The question remains of how to select the optimal perioperative treatment that will maximize benefit for patients while avoiding toxicities from unnecessary therapies. This article reviews currently available evidence supporting preoperative and postoperative therapy in gastroesophageal cancers, with an emphasis on recent practice-changing trials and ongoing areas of investigation, including the role of immune checkpoint inhibition and biomarker-guided treatment.

Publication types

  • Review

MeSH terms

  • Esophageal Neoplasms* / surgery
  • Humans
  • Neoplasm Recurrence, Local
  • Stomach Neoplasms* / drug therapy
  • Stomach Neoplasms* / surgery